NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company's FDA 510(k) clinical study plan. The Company's method comparison study will recruit 135 healthy adult subjects across three sites under an IRB- ...

Qabas is a leading technology provider in Saudi Arabia with a strong reputation for providing high-quality products and services across various sectors. With a deep understanding of the local market and a commitment to excellence, Qabas is well-positioned to drive the adoption of INBS' innovative drug screening solution in the country. NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapi ...

About Intelligent Bio Solutions Inc. Company Contact: Intelligent Bio Solutions Inc. Qabas is a leading technology provider in Saudi Arabia with a strong reputation for providing high-quality products and services across various sectors. With a deep understanding of the local market and a commitment to excellence, Qabas is well-positioned to drive the adoption of INBS' innovative drug screening solution in the country. For more information, visit: http://www.ibs.inc/ Investor & Media Contact: Valter Pinto, ...

Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com The biocompatibility study, conducted in accordance with ISO 10993 standards, involved a thorough evaluation of the system's materials that come into contact with human skin. With the successful completion of the biocompatibility study, INBS has confirmed that all materials used in its system, including the Drug Screening Cartridge, Confirmatory Cartridge and the DSR-Plus Reader, are safe for use in medical device ...

Harry Simeonidis, President and CEO at INBS, commented, "This milestone is an important element of our FDA 510(k) pathway for regulatory clearance, and we are proud to announce its completion. Our development team continues to execute on our plan to meet FDA requirements for our Drug Screening System. We are now poised to move forward with the next stages of our clinical study plan and move closer to bringing our innovative technology to the market." Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medica ...

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its p ...

Dosing and sampling of the second cohort for the study concluded on Thursday, June 27, 2024, marking the completion of this phase and the end of the in-clinic portion of the study. The PK study aims to demonstrate that the Company's fingerprint sweat collection method provides results comparable to those from other specimen matrices, such as blood, saliva, and urine. INBS' first-of-its-kind fingerprint drug screening technology uses fingerprint sweat to provide a quick, hygienic, and easy-to-use method for ...

Doug Heath, Vice president of Global Sales at INBS, commented, "Our reach continues to extend into new sectors, indicating a demand for drug testing beyond just safety-critical industries. We're seeing more businesses taking proactive measures to ensure workplace safety and protect their reputation as responsible employers. We are very pleased to welcome these prominent retail partners into our growing network." For more information, visit: http://www.ibs.inc/ The recently secured accounts employ over 55,00 ...

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the expansion of its customer network within the UK retail sector. This includes the adoption of INBS' Intelligent Fingerprinting Drug Screening System by three prominent UK retailers, among the largest and most recognized in the country. The recently secured accounts employ over 55,000 ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has successfully signed two new major customer accounts within the UK warehouse and logistics sector within the past three months. These accounts employ more than 15,000 individuals at more than 70 locations and will adopt INBS' innovative Intelligent Fingerprinting Drug Screenin ...